The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
Antonio Gonzalez-Martin
No relevant relationships to disclose
Patricia Pautier
Consultant or Advisory Role - AstraZeneca; PharmaMar; Roche
Sven Mahner
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Roche
Research Funding - Roche
Jörn Rau
No relevant relationships to disclose
Nicoletta Colombo
Consultant or Advisory Role - Roche
Honoraria - Roche
Petronella Ottevanger
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Dominique Berton-Rigaud
No relevant relationships to disclose
Andreas Du Bois
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; MSD; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Johnson & Johnson; MSD; PharmaMar; Roche
Ulrich Freudensprung
Employment or Leadership Position - Roche
Ru-Amir Walker
Employment or Leadership Position - Roche
Stock Ownership - Roche
Christian Kurzeder
Honoraria - Roche
Other Remuneration - Roche